6 recruiting, 3 not yet recruiting, 2 completed. 5 Phase 2, 3 Phase 1, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Not yet recruiting 2, Recruiting 2, Completed 1 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Triple -Negative Breast Cancer: new trials by email Literature Review of Triple -Negative Breast Cancer trials Research Report on Triple -Negative Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer Cromolyn, TQB2102, and Panpulimab - Triple -Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 46 | 2027-01-01 | 2026-09-25 |
| Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer Pre-treatment DCE-MRI-based AI model - Breast Neoplasm Female, Triple -Negative Breast Cancer | Recruiting | Fujian Cancer Hospital | 120 | 2026-10-08 | 2026-10-19 | |
| Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Epirubicin and cyclophosphamide followed by paclitaxel oral solution - Triple -Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Liu Shu | 30 | 2026-07-30 | 2026-08-04 |
| Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib) - Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma | Phase 3 | Not yet recruiting | The Netherlands Cancer Institute | 1000 | 2026-04-01 | 2026-03-20 |
| Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer Extended-Dose Interval Immunotherapy, Standard-Dose Interval Immunotherapy - Triple -Negative Breast Cancer, Breast Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 416 | 2025-12-31 | 2026-02-10 |
| Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC Sacituzumab Tirumotecan - Triple -Negative Breast Cancer | Phase 2 | Not yet recruiting | Xijing Hospital | 35 | 2025-08-20 | 2025-07-29 |
| Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy - Breast Cancer Stage IV, Triple -Negative Breast Cancer | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 246 | 2025-02-21 | 2026-04-23 |
| THE-0504 in Patients With Solid Tumors THE-0504 - Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC) | Phase 1 | Recruiting | Thena Biotech S.r.l. | 30 | 2024-11-13 | 2026-06-12 |
| A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha MOv18 IgE - Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 | Recruiting | Epsilogen Ltd | 45 | 2024-09-03 | 2026-04-06 |
| Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer capecitabine - Triple -Negative Breast Cancer | Phase 2 | Completed | Beni-Suef University | 80 | 2021-11-01 | 2025-08-27 |
| Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Biopsy, Chemokine Modulation Therapy, Celecoxib - Triple -Negative Breast Cancer, Estrogen Receptor Negative | Early Phase 1 | Completed | Roswell Park Cancer Institute | 8 | 2019-01-09 | 2023-07-18 |
Triple Negative Breast Neoplasms (11) · Breast Neoplasms (3) · Neoplasms (2) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Breast Diseases (11) · Neoplasms by Site (11) · Skin Diseases (11) · Skin and Connective Tissue Diseases (11) · Neoplasms (9) · Breast Neoplasms (8) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
Capecitabine (2) · pembrolizumab (2) · Benzenesulfonamides (1) · Biopsy (1) · Celecoxib (1) · Cromolyn Sodium (1) · Epirubicin (1) · Interferon alpha-2 (1) · Introns (1) · Neurofibromin 2 (1) · Standard of Care (1) · Uridine Monophosphate (1) · olaparib (1) · poly(I).poly(c12,U) (1)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Beni-Suef University (1) · Epsilogen Ltd (1) · Fudan University (1) · Fujian Cancer Hospital (1) · Liu Shu (1) · Roswell Park Cancer Institute (1) · The Netherlands Cancer Institute (1) · Thena Biotech S.r.l. (1) · Xijing Hospital (1)
China (5) · Egypt (1) · Italy (1) · United Kingdom (1) · United States (1)
Agnes Jager, MD, PhD (1) · Chuangui Song, doctor (1) · Gabe Sonke, MD, PhD (1) · Gennaro Daniele (1) · Marleen Kok, MD, PhD (1) · Rebecca Kristeleit, MD (1) · Shipra Gandhi, MD (1) · Zhimin Shao (1)
2023 (1), 2025 (1)